Agilent Technologies, Inc. (NYSE:A) Shares Purchased by CIBC Asset Management Inc

CIBC Asset Management Inc boosted its stake in Agilent Technologies, Inc. (NYSE:A) by 2.7% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 44,315 shares of the medical research company’s stock after purchasing an additional 1,157 shares during the period. CIBC Asset Management Inc’s holdings in Agilent Technologies were worth $5,953,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. McAdam LLC grew its stake in shares of Agilent Technologies by 3.1% in the third quarter. McAdam LLC now owns 2,531 shares of the medical research company’s stock worth $376,000 after acquiring an additional 77 shares in the last quarter. Brown Brothers Harriman & Co. grew its stake in shares of Agilent Technologies by 13.5% in the third quarter. Brown Brothers Harriman & Co. now owns 646 shares of the medical research company’s stock worth $96,000 after acquiring an additional 77 shares in the last quarter. Rovin Capital UT ADV grew its stake in shares of Agilent Technologies by 1.6% in the third quarter. Rovin Capital UT ADV now owns 5,049 shares of the medical research company’s stock worth $750,000 after acquiring an additional 81 shares in the last quarter. Integrated Advisors Network LLC grew its stake in shares of Agilent Technologies by 2.5% in the third quarter. Integrated Advisors Network LLC now owns 3,582 shares of the medical research company’s stock worth $532,000 after acquiring an additional 86 shares in the last quarter. Finally, Ascent Group LLC grew its stake in shares of Agilent Technologies by 4.1% in the third quarter. Ascent Group LLC now owns 2,209 shares of the medical research company’s stock worth $328,000 after acquiring an additional 87 shares in the last quarter.

Insider Transactions at Agilent Technologies

In other news, CEO Padraig Mcdonnell sold 1,911 shares of the business’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $150.00, for a total transaction of $286,650.00. Following the transaction, the chief executive officer now directly owns 39,652 shares in the company, valued at $5,947,800. The trade was a 4.60 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Agilent Technologies Price Performance

Shares of NYSE:A opened at $137.21 on Thursday. The company has a 50-day simple moving average of $141.13 and a 200-day simple moving average of $139.30. Agilent Technologies, Inc. has a one year low of $124.16 and a one year high of $155.35. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.58 and a current ratio of 2.09. The stock has a market capitalization of $39.15 billion, a price-to-earnings ratio of 31.04, a PEG ratio of 3.65 and a beta of 1.07.

Agilent Technologies (NYSE:A) last announced its earnings results on Monday, November 25th. The medical research company reported $1.46 EPS for the quarter, beating analysts’ consensus estimates of $1.41 by $0.05. Agilent Technologies had a net margin of 19.80% and a return on equity of 25.43%. The business had revenue of $1.70 billion during the quarter, compared to analysts’ expectations of $1.67 billion. During the same period in the prior year, the company earned $1.38 earnings per share. The business’s revenue was up .8% compared to the same quarter last year. On average, analysts predict that Agilent Technologies, Inc. will post 5.56 EPS for the current year.

Agilent Technologies Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 23rd. Stockholders of record on Tuesday, April 1st will be paid a dividend of $0.248 per share. This represents a $0.99 dividend on an annualized basis and a dividend yield of 0.72%. Agilent Technologies’s dividend payout ratio (DPR) is 22.40%.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on A shares. Barclays raised shares of Agilent Technologies from an “underweight” rating to an “equal weight” rating and lifted their price objective for the stock from $135.00 to $145.00 in a research report on Monday, February 10th. Bank of America decreased their price objective on shares of Agilent Technologies from $153.00 to $150.00 and set a “neutral” rating for the company in a research report on Friday, December 13th. Sanford C. Bernstein decreased their price objective on shares of Agilent Technologies from $140.00 to $135.00 and set a “market perform” rating for the company in a research report on Tuesday, November 26th. Citigroup lifted their price objective on shares of Agilent Technologies to $165.00 and gave the stock a “buy” rating in a research report on Thursday, December 19th. Finally, StockNews.com raised shares of Agilent Technologies from a “hold” rating to a “buy” rating in a research report on Tuesday, December 24th. Seven equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $144.38.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.